In a small trial, Mass General Brigham researchers found a drug designed to treat Celiac disease supported a more rapid return to normal activities for patients following COVID.
Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition that can occur after a COVID-19 infection, presenting as high fevers, gastrointestinal symptoms, and life-threatening cardiac injury. A small, randomized clinical trial led by Mass General Brigham investigators found the oral drug larazotide-an experimental drug originally designed to treat Celiac disease-was both safe and effective in treating children with MIS-C. Their results are published in Science Translational Medicine.
While our study is small, its results are…
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We 5guruayurveda.com want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on. For any glitch kindly connect at 5guruayurveda.com
